SQUIRE_2A: SQUIRE, figure 2A

SQUIRE_2AR Documentation

SQUIRE, figure 2A

Description

Kaplan-Meier digitized data from SQUIRE, figure 2A (PMID 26045340). A reported sample size of 1,093 for a primary endpoint of OS in lung cancer.

Usage

SQUIRE_2A

Format

A data frame of 1,093 observations and 3 variables:

time event time (in months)
event OS event indicator (0: no event, 1: event)
arm treatment arms (gem_cis, necitumumab_gem_cis)

Source

Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015; 16: 763–74.

Examples

summary(SQUIRE_2A)

kmplot(SQUIRE_2A)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.